
13207 Ravenna Road PO. Box 249 Chardon, Ohio 44024 216-285-6000 216-269-6000 Clevelanu



UniversityHospitalsHealthSystem

\* GeaugaRegional Hospital

1/7/97

Nuclear Materials Licensing Section U.S. Nuclear Regulatory Commission Region III 801 Warrenville Road Lisle, Illinois 60532-4351

Re: License No. 34-09457-02

To whom it may concern:

As required by 10 CFR 35.14(a), please be advised that, pursuant to the authorization in 35.13(b) and 35.22(b)(2), the Radiation Safety Committee has approved Bruce H. Robson, M.D. as an authorized user for the materials and procedures specified in 35.100, 35.200 and 35.300 excluding Iodine-131 for thyroid carcinoma. Dr. Robson is listed as an authorized user on NRC license No. 34-11232-02 issued to Lake Hospital Systems. A copy is enclosed. The Committee approved Dr. Robson on 12/31/96.

If you need any further information, please feel free to contact us.

Sincerely,

Robert P. Jacobson, MD

Chairman, Radiation Safety Committee

Roberto Subsmillo

RPJ:mcg encl

9701300060 970107 PDR ADOCK 03002788 C PDR

290094

Pm: 1-9-97

JAN 1 3 1997 REGION III

JAN 18 18 3 DH

NRC FORM 574 (10-89)

## U.S. NUCLEAR REGULATORY COMMISSION

是一种,他们是一种,他们也是一种心理的是有一种心理的是一种心理的是一种心理的是一种心理的是一种心理的是一种心理的是一种心理的是一种心理的是一种心理的是一种心理的 No.

## MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such reaterial for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear andirions specified below.

Regulatory Commission now or hereafter in effect a	May 19, 1993 and letter dated June 8, 1993
<ol> <li>Lake Hospital Systems - West Nuclear Medicine Department</li> </ol>	3. License number 34-11232-02 is renewed in its entirety as follows:
2 36000 Euclid Avenue Willoughby, OH 44094	4. Expirition date April 30, 1999
	5. Docket of - 030-18925/34-11232-01 Reference No.
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical 6. Maximum amount that license form 7. Chemical and/or physical 7. Chemical and 7. Chemical an
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceútical identified in 10-CER 35.100
material identified	A. Any A. As needed radiopharmaceutical identified in 10-CER 35.100

Authorized Use: 9.

には私はは世代国にほどはとはとなればなほとは代表には、

- Medical use described in 10 CFR 35.100. A.
- Medical use described in 10 CFR 35.200 (excluding generators and Xenon-133).
- Medical use described in 10 CFR 35.300.

9404080042

IRC Fórm 374A Silven	MATERIALS LICENSE	License I.  34-11232-02  Docket or Reference number				
SUPPLEMENTARY SHEET		030-18925/34-11232-01				
		Amendment No. 10				
		CONDITIONS				
	A. Licensed material in Items 6.A., 6.B. and 6.C. shall be used only at the licensee's facilities located at Lake Hospital Systems West, 36000 Euclid Avenue, Willoughby, Ohio.					
В.	thurnid carcinoma treatment)	A., 6.B. and 6.C. (excluding iodine-131 for shall be used only at the licensee's facilities ems East, Washington at Liberty-Street,				
1. Radia	Radiation Safety Officer: Francis A. Greicius, M.D.					
2. Lîcer super	the second of th					
Autho	orized Users					
Α.	Howard Potash, M.D.	10-GFR-35-100, 35.200 (excluding generators and Xenon-133), and 35.300.				
В.	James Roda, M.D.	10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300 (excluding Iodine-131 for thyroid carcinoma).				
c.	Victor J. DeMarco, M.D.	10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300 (excluding Iodine-131 for thyroid carcinoma).				
D.	Bela Frank Ballo, M.D.	10-CFR 35:100, 35.200 (excluding generators and Xenon-133), and 35.300 (excluding Iodine-131 for thyroid carcinoma).				
Ε.	Francis A. Greicius, M.D.	10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300 (excluding Iodine-131 for thyroid carcinoma).				
F.	Bruce H. Robson, M.D.	10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300 (excluding Iodine-131 for thyroid carcinoma).				
G.	David Alan Steiger, M.D.	10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300 (excluding Iodine-131 for thyroid carcinoma).				
*						

NRC Form 374A

License number

MATERIALS LICENSE SUPPLEMENTARY SHEET Docket or Reference number 030-18925/34-11232-01

Amendment No. 10

H. Deodutt V. Patel, M.D. 10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300 (excluding jodine-131 for thyroid carcinoma treatment).

- Bon Chul Koo, M.D. I.
- 10 CFR 35.100, and 35.200 (excluding generators and Xenon-133).
- David Wymer, M.D.
- 10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300; -
- David J. Horejs, M.D.
- 10 CFR 35.100, 35.200 (excluding generators and Xenon-133), and 35.300 ---
- Ronald A. Siwik, M.D.
- 10 CFR 35.100, 35:200 and 35.300.
- Howard J. Klein, M.D.
- 10 CFR-35.100, 35,200 and 35,300.
- Except as specifically provided otherwise in this ficense, the licensee shall conduct its program procedures contained except for minor chain 10 CFR 35.31. The unless the statement and correspondence at the statement of conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures. listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations
  - Application dated May 19, 1993 (with attachments); and
  - Letters dated June 8, 1993 and February 25, 1994. 第一次一次一次一个

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Licensing Section, Region III

DATE: 1-16-97

## CORRESPONDENCE CLARIFICATION SHEET

REV	TEWER:	BJ HOLT					
LICE	ENSEE:	Univ H	4,0,				
LICE	ENSE NUMBER:		57-02				
corr	ior ciedi Milat action	cate which of	received from the above equired: Please review the following applies, a	A Section			
	Additional Informat Process in as a new	tion to Contro w action, addi	l No. tional information, and	no fee required			
	Process as new licensing action. Review has already been started on combined with current in-house action.						
	Can be combined wit	ch Control No.	Review h	as not started.			
	Appears to be infor	rmation for the	e license file - file it				
П	Licensee is adding	Nuclear Pharma	acists.				
	Amendment is necess	ary /	Amendment is not necessar Information for license	ry file)			
	icensee is adding authorized users.						
	A check is included	*	No check is included				
	Amendment is necess	ary	Amendment is not necess (This is a Notification	sary / fg			
	Process in as a new licensing action:						
	A. Amendment B. Renewal C. New License App	lication					
	Other:						
		Thank You Fo	r Your Help!!!	10/16/96			